BioTuesdays
Amarin

Analysts downgrade Amarin; PTs cut to $3

Analysts for H.C. Wainwright and SVB Securities downgraded Amarin (NASDAQ:AMRN) to “neutral” from “ buy” and to “market perform” from “outperform,” respectively. Both analysts cut their prices targets to $3 from $10...

Talking mental health with Chris Wang of Shimmer

Chris Wang, Co-founder and CEO of Shimmer As co-founder and CEO of Shimmer, a provider of a science-backed process to reduce stress and anxiety, Chris Wang took an early interest in social impact consulting at her first...

Talis-Logo

BTIG cuts Talis Biomedical to sell; PT $1

BTIG downgraded Talis Biomedical (NASDAQ:TLIS) to “sell” from “neutral” with a price target of $1, citing a delay in the beta-phase rollout of the Talis One COVID-19 diagnostic, which was planned for the first quarter...

Pardes Biosciences

SVB Leerink starts Pardes Biosciences at OP; PT $18

SVB Leerink launched coverage of Pardes Biosciences (NASDAQ:PRDS) with an “outperform” rating and $18 price target. The stock closed at $5.54 on March 14. Pardes is a clinical-stage biopharmaceutical company created to...